Customizable COVID-19 Testing Packages Launched to Help Manage and Treat Virus

BioAgilytix in the News

December 15, 2015

Building Partnerships with Other CROs

By nature, the idea of CRO partnerships is attractive to Executives and Business Development Teams because such alignments equip their CRO with a more comprehensive, and thus competitive list of service offerings. This article is my attempt to share the dos, and most importantly, the don’ts in establishing mutually beneficial alliances with other CROs.

Read More

September 23, 2015

How to Win Client Trust as a CRO

The act of building trust with your pharmaceutical and biotech clients is similar to how trust is built between friends – both require time, mutual respect and appreciation. This article discuesses how numerous teams within the CRO and sponsor organization work together to establish trust, and ultimately a fruitful partnership.

Read More

August 28, 2015

How to Set up a Successful CRO by Surrounding Yourself with the Right Team Members

It is very important for executives of CRO companies to recognize that the most critical factor in making a CRO successful is the people that you hire. A CRO can have the latest and greatest platform instruments and technology, but these novel tools would be a wasted investment without quality scientists.

Read More

August 17, 2015

Durham’s BioAgilytix Continues Growth Spurt; Plans to Add More Jobs

BioAgilytix doubled its customer base from 2013 to 2014 and already doubled again by August of this year. The company has 60 percent organic year-over-year growth and Datin expects to acquire a company in Europe by the end of the year. Last year, it worked with 12 of the 25 largest pharmaceutical and biotechnology companies, a figure that has increased to 19 this year.

Read More

July 1, 2015

Starting a CRO on Personal Credit

Bioanalysis Zone Regardless of the size of the CRO, the quality of the work that I received was most dependent on the specific team managing and working on my projects.…

Read More

May 8, 2015

Evaluating the Immunogenicity of Antibody–drug Conjugates

Antibody–drug conjugates (ADCs) represent an innovative therapeutic approach that provides novel treatment options and hope for patients with cancer and infectious disease. In fact, ADCs are quickly becoming one of the fastest growing classes of oncology therapeutics in the pipelines of many pharmaceutical companies.

Read More